Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

SXTPW

60 Degrees Pharmaceuticals (SXTPW)

60 Degrees Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:SXTPW
日付受信時刻ニュースソース見出しコード企業名
2025/02/2100 : 36GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock SplitNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/02/1207 : 23Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/02/1202 : 59GlobeNewswire Inc.Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/02/0706 : 41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/02/0704 : 07GlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/02/0700 : 04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/02/0523 : 22GlobeNewswire Inc.60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/3107 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/3104 : 20GlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/3022 : 28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/2922 : 00GlobeNewswire Inc.60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/2906 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/2822 : 01GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/2506 : 52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/2506 : 51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/2207 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/2206 : 58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/0906 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2025/01/0822 : 02GlobeNewswire Inc.60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/12/2322 : 57GlobeNewswire Inc.Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/12/1910 : 35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/12/1122 : 56GlobeNewswire Inc.60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/12/1007 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/11/2208 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/11/1504 : 31GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/11/1503 : 44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/11/0707 : 26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/10/1604 : 46Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/10/0821 : 17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
2024/10/0322 : 02GlobeNewswire Inc.60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTPW